On Jun. 25, 2018, AbbVie and Calibr, a nonprofit drug discovery division of Scripps Research, announced a collaboration for next generation T-cell therapies.

AbbVie paid Calibr an upfront license fee and gained exclusive access to Calibr’s switchable CAR-T platform for a term of up to four years.